#Infigratinib
LightNews LightNews
adee-esp.bsky.social
Consulta todos los detalles en nuestro artículo:

adee.es/actualizacio...

#Infigratinib #Acondroplasia #AvancesCientíficos
January 13, 2025 at 7:25 PM
runningdoc.bsky.social
Super cool story of innovation and persistence in #NEJM. You might remember #infigratinib AKA #BGJ398, which recently lost FDA approval for FGFR2+ #cholangiocarcinoma. Low doses of #infigratinib are promising in a rare genetic skeletal condition #achondroplasia #medsky www.nejm.org/doi/full/10....
Oral Infigratinib Therapy in Children with Achondroplasia | NEJM
Achondroplasia is a genetic skeletal condition that results in disproportionately short stature and medical complications throughout life. Infigratinib is an orally bioavailable FGFR1–3 selective t...
www.nejm.org
November 18, 2024 at 1:56 PM
tsubodaisuki.bsky.social
FGFR1～3阻害薬infigratinib、軟骨無形成症に有効 - 時事メディカル
news.google.com/rss/articles/CBMiS0FVX3lxTE9TYVJCQk1FallVM1dZOHFsVThsZmRreTRyYW1FeDY0NGdMcXBIZW4yOXVEUFlGUlgtU08xbFEzc3BENHUzak1seFBuQQ?oc=5
March 5, 2025 at 9:09 AM
livermd.bsky.social
@US_FDA approves #Futibatinib for FGFR2+ Advanced #CCA. It’s been a great 2 years for BTC survivors with addition of #durvalumab + gem/cis as well as #ivosidenib (IDH1) #infigratinib #pemigatinib (FGFR2 fusion) #dabrafenib #trametinib (BRAF V600E)
December 2, 2024 at 11:35 PM
runningdoc.bsky.social
Nine months after @fda.gov withdrew the accelerated approval for FGFR2+ #cholangiocarcinoma we are witnessing a promising attempt to repurpose the compound. Relatively low doses of infigratinib can help children with #achondroplasia (FGFR3+ hereditary disease) www.nejm.org/doi/full/10....
Oral Infigratinib Therapy in Children with Achondroplasia | NEJM
Achondroplasia is a genetic skeletal condition that results in disproportionately short stature and medical complications throughout life. Infigratinib is an orally bioavailable FGFR1–3 selective t...
www.nejm.org
February 27, 2025 at 3:53 PM
nejm.org
Oral Infigratinib in Children with Achondroplasia (phase 2 study) nej.md/3Z4xCSe

Blinatumomab in B-Cell Acute Lymphoblastic Leukemia (AALL1731 phase 3 trial) nej.md/49CVkc1

Subscribe to NEJM for the latest medical research: nej.md/subscribe
February 27, 2025 at 2:08 PM
onco404.bsky.social
📌 FGFR inhibitors (like pemigatinib, erdafitinib, infigratinib) have transformed care for FGFR-altered cholangiocarcinoma.

🚨 A new study analysis led to a model characterizing the biology of acquired resistance 🔍

#AnnalsOfOncology

#Onco404 #Cholangiocarcinoma #DrugResistance #Oncology #oncsky
March 18, 2025 at 3:33 PM
medicine.stitches.today
Oral infigratinib significantly increased height growth in children with achondroplasia with manageable safety outcomes over 18 months.

by Savarirayan R, De Bergua JM (...) Rogoff D et 23 al. in N Engl J Med #MedSky

📖 read the article: http://www.nejm.org/doi/10.1056/NEJMoa2411790
March 8, 2025 at 4:27 PM
tsubodaisuki.bsky.social
FGFR1～3阻害薬infigratinib、軟骨無形成症に有効 - 時事メディカル
news.google.com/rss/articles/CBMiS0FVX3lxTE9TYVJCQk1FallVM1dZOHFsVThsZmRreTRyYW1FeDY0NGdMcXBIZW4yOXVEUFlGUlgtU08xbFEzc3BENHUzak1seFBuQQ?oc=5
March 5, 2025 at 8:09 AM
adee-esp.bsky.social
🌟 2/3– ¿Qué es Infigratinib?
Es un inhibidor selectivo de FGFR1-3 diseñado para abordar las señales moleculares que limitan el crecimiento óseo en personas con acondroplasia. Su administración oral lo diferencia como una alternativa menos invasiva.
January 13, 2025 at 7:25 PM
tsubodaisuki.bsky.social
FGFR1～3阻害薬infigratinib、軟骨無形成症に有効 - 時事メディカル
news.google.com/rss/articles/CBMiS0FVX3lxTE9TYVJCQk1FallVM1dZOHFsVThsZmRreTRyYW1FeDY0NGdMcXBIZW4yOXVEUFlGUlgtU08xbFEzc3BENHUzak1seFBuQQ?oc=5
March 5, 2025 at 7:09 AM
shihcheng.bsky.social
Oral infigratinib, a FGFR1-3 inhibitor, shows promise in improving growth in children aged 3-11 with achondroplasia. Phase 2: 72 kids. #GrowthBreakthrough PMID:39555818, N Engl J Med 2025, @NEJM https://doi.org/10.1056/NEJMoa2411790 #Medsky 🧪
https://doi.org/10.1056/NEJMoa2411790
No description available
doi.org
March 10, 2025 at 11:10 AM
stocktitan.net
#BBIO BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

https://www.stocktitan.net/news/BBIO/bridge-bio-pharma-announces-publication-in-the-new-england-journal-lmawkstxwddc.html
November 18, 2024 at 10:30 AM
osteoporosis-nl.bsky.social
In mouse model of hypochondroplasia, infigratinib resulted in significant improvement in skeletal growth. B Demuynck et al. JBMR 24 June 2025 shorturl.at/p2z3I …supports clinical results from the Phase 2 study of Savarirayan in NEJM 2024 shorturl.at/pq046
Infigratinib low dose therapy is an effective strategy to treat hypochondroplasia
Abstract. Hypochondroplasia is a rare genetic form of skeletal dysplasia, caused by gain-of-function pathogenic variants in the fibroblast growth factor re
shorturl.at
July 7, 2025 at 7:26 AM
medicine.stitches.today
Oral infigratinib safely increased height growth in children with achondroplasia, showing promise for future treatments.

by Savarirayan R, De Bergua JM (...) Hoover-Fong J et 21 al. in N Engl J Med

📖 read the article: https://www.nejm.org/doi/10.1056/NEJMoa2411790
November 27, 2024 at 6:38 PM
tsubodaisuki.bsky.social
FGFR1～3阻害薬infigratinib、軟骨無形成症に有効 - 時事メディカル
news.google.com/rss/articles/CBMiS0FVX3lxTE9TYVJCQk1FallVM1dZOHFsVThsZmRreTRyYW1FeDY0NGdMcXBIZW4yOXVEUFlGUlgtU08xbFEzc3BENHUzak1seFBuQQ?oc=5
March 5, 2025 at 12:09 PM
medchemexpress.bsky.social
🚀From Bench to Paper | New in Signal Transduction & Targeted Therapy: #Olverembatinib shows strong activity in #SDH-deficient #GIST (PFS ~26 months, CBR ~85%).
👍 The study used high-quality reagents (#bFGF, #hydrocortisone, #Infigratinib and #insulin) from MedChemExpress.
November 10, 2025 at 11:00 PM
tsubodaisuki.bsky.social
FGFR1～3阻害薬infigratinib、軟骨無形成症に有効 - 時事メディカル
news.google.com/rss/articles/CBMiS0FVX3lxTE9TYVJCQk1FallVM1dZOHFsVThsZmRreTRyYW1FeDY0NGdMcXBIZW4yOXVEUFlGUlgtU08xbFEzc3BENHUzak1seFBuQQ?oc=5
March 5, 2025 at 10:09 AM
tsubodaisuki.bsky.social
FGFR1～3阻害薬infigratinib、軟骨無形成症に有効 - 時事メディカル
news.google.com/rss/articles/CBMiS0FVX3lxTE9TYVJCQk1FallVM1dZOHFsVThsZmRreTRyYW1FeDY0NGdMcXBIZW4yOXVEUFlGUlgtU08xbFEzc3BENHUzak1seFBuQQ?oc=5
March 5, 2025 at 11:09 AM
adee-esp.bsky.social
🔬 Actualización sobre acondroplasia

El ensayo clínico de Fase 3 de Infigratinib, un posible tratamiento oral para acondroplasia, ha alcanzado un hito clave al completar su reclutamiento.

📖 Más info: adee.es/actualizacio...
January 13, 2025 at 7:26 PM
thealexknapp.bsky.social
Bridgebio has granted an exclusive license to Kyowa Kirin to market its skeletal dysplasia treatment infigratinib in Japan. The deal includes an upfront payment of $100 million to BridgeBio as well as royalties.

bridgebio.com/news/bridgeb...
BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an...
– BridgeBio grants Kyowa Kirin exclusive license to develop and commercialize infigratinib for skeletal dysplasias in Japan – BridgeBio to receive upfront payment of USD 100 million with royalties...
bridgebio.com
February 7, 2024 at 2:53 PM
tsubodaisuki.bsky.social
FGFR1～3阻害薬infigratinib、軟骨無形成症に有効 - 時事メディカル
news.google.com/rss/articles/CBMiS0FVX3lxTE9TYVJCQk1FallVM1dZOHFsVThsZmRreTRyYW1FeDY0NGdMcXBIZW4yOXVEUFlGUlgtU08xbFEzc3BENHUzak1seFBuQQ?oc=5
March 5, 2025 at 1:09 PM
tsubodaisuki.bsky.social
FGFR1～3阻害薬infigratinib、軟骨無形成症に有効 - 時事メディカル
news.google.com/rss/articles/CBMiS0FVX3lxTE9TYVJCQk1FallVM1dZOHFsVThsZmRreTRyYW1FeDY0NGdMcXBIZW4yOXVEUFlGUlgtU08xbFEzc3BENHUzak1seFBuQQ?oc=5
March 5, 2025 at 2:09 PM